GIULIANI, Nicola
 Distribuzione geografica
Continente #
EU - Europa 177
NA - Nord America 57
AS - Asia 28
OC - Oceania 4
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 269
Nazione #
DE - Germania 79
IT - Italia 68
US - Stati Uniti d'America 54
CN - Cina 11
IE - Irlanda 6
FR - Francia 5
GB - Regno Unito 5
IN - India 5
AU - Australia 4
MY - Malesia 4
UA - Ucraina 3
AR - Argentina 2
BY - Bielorussia 2
CA - Canada 2
CZ - Repubblica Ceca 2
JP - Giappone 2
MK - Macedonia 2
AT - Austria 1
EU - Europa 1
FI - Finlandia 1
HK - Hong Kong 1
KR - Corea 1
LB - Libano 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MX - Messico 1
PT - Portogallo 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
Totale 269
Città #
Parma 38
Hangzhou 8
Dublin 6
Mcallen 6
Columbus 5
Bologna 3
Medolla 3
Palermo 3
Sant'ilario D'enza 3
Acerra 2
Aylmer 2
Kepala Batas 2
Kingston 2
Kuala Lumpur 2
Minsk 2
Neviano degli Arduini 2
New York 2
Red Bluff 2
Rome 2
Sydney 2
Würzburg 2
Ashburn 1
Auburn 1
Baltimore 1
Bangor 1
Bari 1
Beirut 1
Bethesda 1
Boardman 1
Boston 1
Burghausen 1
Cambridge 1
Canberra 1
Cavaria Con Premezzo 1
Changsha 1
Chicago 1
Chongqing 1
College Station 1
Dallas 1
Dartford 1
Delhi 1
Fort Campbell 1
Frankfurt am Main 1
Franklin 1
Garza García 1
Glasgow 1
Helsinki 1
Hilton Head Island 1
Hoboken 1
Köln 1
Los Angeles 1
Luxembourg 1
Madison 1
Martin 1
Milan 1
Oxford 1
Prilep 1
Rio Saliceto 1
Rockville 1
San Diego 1
San Jose 1
Seoul 1
Shanghai 1
Singapore 1
Toledo 1
Tucson 1
Tübingen 1
Verona 1
Vienna 1
Villa Guardia 1
Virginia Beach 1
Watford 1
Worcester 1
Zionsville 1
Totale 152
Nome #
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation, file e177fbc4-0d1f-50b0-e053-d805fe0adaee 46
The new tumor suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of pro-angiogenic molecules by myeloma cells and suppresses hypoxia inducible factor (HIF)-1{alpha} activity being involved in myeloma-induced angiogenesis., file e177fbc4-1e1f-50b0-e053-d805fe0adaee 39
Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated Multiple Myeloma patients, file e177fbc4-2516-50b0-e053-d805fe0adaee 26
GPNA inhibits the sodium-independent transport system l for neutral amino acids, file e177fbc5-83c4-50b0-e053-d805fe0adaee 22
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition, file e177fbc4-13c6-50b0-e053-d805fe0adaee 18
[18F](2S,4R)-4-Fluoroglutamine as a New Positron Emission Tomography Tracer in Myeloma, file e177fbc7-f72e-50b0-e053-d805fe0adaee 16
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients, file e177fbc4-17a7-50b0-e053-d805fe0adaee 15
Neurofibromatosis type I and multiple myeloma coexistence: A possible link?, file e177fbc8-1891-50b0-e053-d805fe0adaee 12
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease, file e177fbc4-229b-50b0-e053-d805fe0adaee 9
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20, file e177fbc5-32d5-50b0-e053-d805fe0adaee 5
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target, file e177fbc5-32d8-50b0-e053-d805fe0adaee 5
Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia, file e177fbc4-09d6-50b0-e053-d805fe0adaee 4
IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma, file e177fbc4-13c7-50b0-e053-d805fe0adaee 4
Osteogenic differentiation of mesenchymal stem cells in multiple myeloma: identification of potential therapeutic targets, file e177fbc4-1c9d-50b0-e053-d805fe0adaee 4
Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells, file e177fbc4-2afe-50b0-e053-d805fe0adaee 4
Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction, file e177fbc4-3c28-50b0-e053-d805fe0adaee 4
Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo, file e177fbc5-29ee-50b0-e053-d805fe0adaee 4
OPG/RANKL system imbalance in a case of hepatitis C-associated osteosclerosis: the pathogenetic key?, file e177fbc4-16bc-50b0-e053-d805fe0adaee 3
Telomere Dysfunction Drives Aberrant Hematopoietic Differentiation and Myelodysplastic Syndrome, file e177fbc5-2c24-50b0-e053-d805fe0adaee 3
Expression pattern and biological significance of the lncRNA ST3GAL6-AS1 in multiple myeloma, file e177fbc7-d16b-50b0-e053-d805fe0adaee 3
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability, file e177fbc8-0582-50b0-e053-d805fe0adaee 3
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells, file e177fbc8-12e3-50b0-e053-d805fe0adaee 3
Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment, file e177fbc4-1da5-50b0-e053-d805fe0adaee 2
Pro-angiogenetic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship with myeloma-induced angiogenesis, file e177fbc4-2318-50b0-e053-d805fe0adaee 2
Glutamine dependence and PIK3CA mutations in colon-rectal cancer cells: ATF4 enters the stage, file e177fbc5-3fe1-50b0-e053-d805fe0adaee 2
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial, file e177fbc7-cbae-50b0-e053-d805fe0adaee 2
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies, file e177fbc8-1139-50b0-e053-d805fe0adaee 2
Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation, file e177fbc5-310e-50b0-e053-d805fe0adaee 1
The role of proteasome inhibitors in multiple myeloma bone disease and bone metastasis: Effects on osteoblasts and osteocytes, file e177fbc7-cb50-50b0-e053-d805fe0adaee 1
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?, file e177fbc7-d1ea-50b0-e053-d805fe0adaee 1
Role of 1q21 in multiple myeloma: From pathogenesis to possible therapeutic targets, file e177fbc7-da10-50b0-e053-d805fe0adaee 1
Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma, file e177fbc7-edad-50b0-e053-d805fe0adaee 1
Functional consequences of low activity of transport system a for neutral amino acids in human bone marrow mesenchymal stem cells, file e177fbc7-fb00-50b0-e053-d805fe0adaee 1
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents, file e177fbc8-09df-50b0-e053-d805fe0adaee 1
Application of next-generation sequencing for the genomic characterization of patients with smoldering myeloma, file e177fbc8-1217-50b0-e053-d805fe0adaee 1
Totale 270
Categoria #
all - tutte 655
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 655


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 3 1
2021/202233 0 6 2 1 0 1 17 1 1 0 1 3
2022/202335 2 0 2 12 0 5 1 2 8 0 2 1
2023/202416 2 0 2 0 0 0 2 3 1 1 5 0
Totale 270